Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicines Patent Pool Adds Four Board Members

This article was originally published in Scrip

Executive Summary

The Medicines Patent Pool has appointed four new board members; Claudia Chamas, Michel Manon, Brian Tempest and Jayashree Watal. Chamas is a senior researcher at Brazil's Oswaldo Cruz Foundation and has served as representative of the Ministry of Health at the Brazilian Interministerial Group on Intellectual Property and as vice-chair of the WHO Consultative Expert Working Group on research and development (CEWG). Manon, former director for Bristol-Myers Squibb, held various other senior roles at the company including medical director. Tempest was previously at Ranbaxy where he was CEO, managing director and regional director-Far East and regional-director-Middle East & Africa for GlaxoSmithKline (GSK). Currently Tempest is advisor to the United Nations Conference on trade and development and holds non-executive director status in various Indian healthcare and pharma companies. Watal is currently counsellor in the intellectual property division of the Word Trade Organization and has over 22 years' experience in the Indian government working on policy, diplomacy, research and IP rights issue.

You may also be interested in...

Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?

How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.

Adherence Issues Add Weight To Digital Trials Push

Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.

Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus

This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts